The Evaluation of Patients with Severe COVID-19 Pneumonia Who are Recieving Favipiravir Treatment


Ozturk S., Colak O., Kavas S., Ozturk Engin D., Diktas Tahtasakal S., Erdogan Ari D., ...More

MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, vol.10, 2021 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 10
  • Publication Date: 2021
  • Doi Number: 10.4274/mjima.galenos.2021.2020.22
  • Journal Name: MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS
  • Journal Indexes: Emerging Sources Citation Index, Scopus
  • Keywords: COVID-19, SARS-CoV-2, favipiravir, steroid, CORTICOSTEROID-THERAPY, RESPIRATORY SYNDROME, SARS

Abstract

Introduction: There is no known specific treatment for Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Our retrospective study evaluates the effectiveness of steroid treatment and the factors affecting treatment in patients with severe Coronavirus disease-2019 (COVID-19) pneumonia that received favipiravir treatment.